STRATEC SE : Strong second half anticipated to achieve guidance
>Second quarter below expectations - The final H1 results confirm the preliminary results, which were published two weeks ago. H1 revenues of €137.2m (-15.2% in constant currencies were considerably below our € 155.8m. Q2 revenues showed a decline of c. 28% in constant currencies. The company reported lower pandemic related revenues as well as supply constraints and order backlogs as major reasons for the weak development. Hence, delivery backlogs have increased massi...STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.